 Abeona Therapeutics Incs NASDAQ: ABEO stock does not reflect the companys in-house manufacturing capabilities and pipeline, according to Cantor Fitzgerald. The Abeona Therapeutics Analyst: Kristen Kluska upgraded Abeona Therapeutics from Neutral to Overweight while maintaining the price target at 4. 